GSK shares hit as analyst touts potential of Merck’s experimental HIV drug; Interleukin Genetics slashes staff; Trillium looks for partners
⇨ Gilead and GlaxoSmithKline have been getting the lion’s share of the attention for new HIV drugs, but Citi’s Andrew Baum says that Merck’s experimental …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
